11/08/2025 22:15
Vertex Presents Updated Phase 1/2 Data From RUBY-3 Study That Continue to Demonstrate Best-in-Class Potential for Povetacicept in Adults with IgA Nephropathy and Primary Membranous Nephropathy at American Society of Nephrology Kidney Week

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced updated data for povetacicept (pove) in IgA nephropathy (IgAN) and primary membranous nephropathy (pMN) from the ongoing RUBY-3 trial at the American Society of Nephrology (ASN) Kidney Week 2025 in Houston, Texas. Pove is an investigational recombinant fusion protein therapeutic and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines. Pove is the only BAFF+APRIL inhibitor i...

AFP journalists Christina Assi and Dylan Collins to speak at the Press Freedom Center Forum

AFP journalists Christina Assi and Dylan Collins will speak at the Press Freedom Center Forum to share their experience of the Israeli shelling in southern Lebanon on 13 October 2023. The event will take place on 12 March 2025 at the National Press Club in Washington, D.C.

AFP journalists Christina Assi and Dylan Collins will speak at the Press Freedom Center Forum to share their experience of the Israeli shelling in southern Lebanon on 13 October 2023. The event will take place on 12 March 2025 at the National Press Club in Washington, D.C.
12/02/2025 13:00
Aurigene Oncology Limited Announces Encouraging Initial Data From 1st Two Cohorts of Phase 1 Study of AUR112, an Oral Small Molecule Inhibitor of MALT1, in Relapsed/Refractory Lymphoid Malignancies

Aurigene Oncology Limited, a clinical-stage biopharmaceutical company developing novel therapies in oncology, today announced initial clinical results from 1st two cohorts of its ongoing Phase 1 clinical trial evaluating AUR112 in patients with relapsed or refractory lymphoid malignancies. Early findings show that AUR112 is safe, well tolerated, demonstrating meaningful clinical activity, with objective responses observed across multiple lymphoma subtypes, including Mantle Cell Lymphoma (MCL) a...

12/02/2025 13:00
Luma AI Opens for International Business With Former WPP Executive Jason Day Leading New London Office

Luma AI, the frontier artificial intelligence company building multimodal AGI intelligence and known for its flagship product Dream Machine, today announced a major step in its global expansion with the opening of its first international office in London, UK. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251202217704/en/LUMA AI OPENS FOR INTERNATIONAL BUSINESS WITH FORMER WPP EXECUTIVE JASON DAY LEADING NEW LONDON OFFICE As creative...

12/02/2025 13:00
AdvanCell Initiates Phase 2 Expansion Trial of ADVC001, a Novel Targeted Alpha Therapy for Prostate Cancer

AdvanCell, a clinical-stage radiopharmaceutical company developing innovative targeted alpha therapies for cancer, today announced the initiation of the TheraPb Phase 2 expansion trial (NCT05720130) evaluating its lead investigational candidate, ADVC001, in metastatic prostate cancer. The news follows the encouraging Phase 1b dose escalation results presented at the European Society for Medical Oncology (ESMO) 2025 congress that showed a favorable safety profile and compelling anti-tumor activi...

Produits & services
Bangkok post

AFP photojournalist Ina Fassbender awarded first prize in the 2024 VDS Sports Photo Competition

Ina Fassbender secured first place for her photograph ‘Looking Forward to Euro’, taken in Essen during the 2024 UEFA European football championship.

Ina Fassbender secured first place for her photograph ‘Looking Forward to Euro’, taken in Essen during the 2024 UEFA European football championship.
Communiqués de presse
Cision-PR Newswire

Phil Chetwynd on France 24: AI and the Future of Journalism

AFP’s Global News Director, Phil Chetwynd, appeared on France 24’s Scoop on Friday, 7 February, to discuss artificial intelligence and its impact on journalism.

AFP’s Global News Director, Phil Chetwynd, appeared on France 24’s Scoop on Friday, 7 February, to discuss artificial intelligence and its impact on journalism.
Text

Discover
Subscribe to